StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Incyte (INCY) PT Lowered to $87 at RBC Capital, 'Buyers on Weakness'
February 8, 2022 3:54 PM
RBC Capital analyst Brian Abrahams lowered the price target on Incyte (NASDAQ: INCY) to $87.00 (from $90.00) while maintaining an ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Analyst PT Change
Next Articles
Incyte (INCY) Reiterated at Buy by Truist, Dip is a Buying Opportunity, Opzelura Launch is Key Highlight
February 8, 2022 1:31 PM
Incyte (INCY) Reiterated at Market Perform by BMO Capital, 2022 All About Opzelura Revenues
February 8, 2022 8:15 AM
Mizuho Securities Reiterates Neutral Rating on Incyte (INCY)
February 8, 2022 7:53 AM
Form 8-K INCYTE CORP For: Feb 08
February 8, 2022 7:18 AM
Incyte (INCY) Misses Q4 EPS by 76c
February 8, 2022 7:05 AM
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
February 8, 2022 7:00 AM
Form SC 13G/A INCYTE CORP Filed by: WELLINGTON MANAGEMENT GROUP LLP
February 4, 2022 9:18 AM
